JP2012507033A5 - - Google Patents

Download PDF

Info

Publication number
JP2012507033A5
JP2012507033A5 JP2011534536A JP2011534536A JP2012507033A5 JP 2012507033 A5 JP2012507033 A5 JP 2012507033A5 JP 2011534536 A JP2011534536 A JP 2011534536A JP 2011534536 A JP2011534536 A JP 2011534536A JP 2012507033 A5 JP2012507033 A5 JP 2012507033A5
Authority
JP
Japan
Prior art keywords
spectrum
monoclonal antibody
growth factor
factor receptor
epidermal growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011534536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507033A (ja
JP4997345B2 (ja
Filing date
Publication date
Priority claimed from US12/321,394 external-priority patent/US7858390B2/en
Application filed filed Critical
Publication of JP2012507033A publication Critical patent/JP2012507033A/ja
Publication of JP2012507033A5 publication Critical patent/JP2012507033A5/ja
Application granted granted Critical
Publication of JP4997345B2 publication Critical patent/JP4997345B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011534536A 2009-01-20 2009-11-20 Egfr経路を標的にする薬物による治療のための結腸直腸癌患者の選択 Expired - Fee Related JP4997345B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/321,394 2009-01-20
US12/321,394 US7858390B2 (en) 2006-03-31 2009-01-20 Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
PCT/US2009/006267 WO2010085234A1 (en) 2009-01-20 2009-11-20 Selection of colorectal cancer patients for treatment with drugs targeting egfr pathway

Publications (3)

Publication Number Publication Date
JP2012507033A JP2012507033A (ja) 2012-03-22
JP2012507033A5 true JP2012507033A5 (enExample) 2012-05-10
JP4997345B2 JP4997345B2 (ja) 2012-08-08

Family

ID=41571343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011534536A Expired - Fee Related JP4997345B2 (ja) 2009-01-20 2009-11-20 Egfr経路を標的にする薬物による治療のための結腸直腸癌患者の選択

Country Status (10)

Country Link
US (1) US7858390B2 (enExample)
EP (1) EP2347261B1 (enExample)
JP (1) JP4997345B2 (enExample)
KR (1) KR101131231B1 (enExample)
AU (1) AU2009338173B2 (enExample)
CA (1) CA2744394A1 (enExample)
ES (1) ES2392805T3 (enExample)
IL (1) IL211944A (enExample)
TW (1) TWI366671B (enExample)
WO (1) WO2010085234A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7858390B2 (en) 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway
US7906342B2 (en) * 2006-03-31 2011-03-15 Biodesix, Inc. Monitoring treatment of cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples
US7736905B2 (en) 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
EP2539704A4 (en) * 2010-02-24 2015-12-02 Biodesix Inc CANCER PATIENT SELECTION FOR ADMINISTRATION OF THERAPEUTIC AGENTS USING MASS SPECTROMETRY ANALYSIS
EP2668504A4 (en) 2011-01-28 2015-06-10 Biodesix Inc PREDICTIVE TEST FOR SELECTING PATIENTS WITH METASTATIC BREAST CANCERS TO RECEIVE HORMONE THERAPY AND POLY THERAPY
EP2864792A1 (en) 2012-06-26 2015-04-29 Biodesix, Inc. Mass-spectral method for selection, and de-selection, of cancer patients for treatment with immune response generating therapies
US8718996B2 (en) 2012-07-05 2014-05-06 Biodesix, Inc. Method for predicting whether a cancer patient will not benefit from platinum-based chemotherapy agents
US10037874B2 (en) 2014-12-03 2018-07-31 Biodesix, Inc. Early detection of hepatocellular carcinoma in high risk populations using MALDI-TOF mass spectrometry
CN112710723B (zh) 2015-07-13 2024-11-12 佰欧迪塞克斯公司 受益于pd-1抗体药物的肺癌患者的预测性测试和分类器开发方法
BR112018014870A2 (pt) * 2016-01-21 2018-12-11 Protein Dynamic Solutions Llc método e sistema para análise de dados espectrais
WO2017136139A1 (en) 2016-02-01 2017-08-10 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (il2) therapy
WO2017176423A1 (en) 2016-04-08 2017-10-12 Biodesix, Inc. Classifier generation methods and predictive test for ovarian cancer patient prognosis under platinum chemotherapy
EP3566054A4 (en) 2017-01-05 2020-12-09 Biodesix, Inc. PROCESS FOR IDENTIFYING CANCER PATIENTS LIKELY TO BENEFIT FROM IMMUNOTHERAPY FOR LASTING SUSTAINABLE SUB-GROUPS OF PATIENTS WHO HAVE A BAD PROGNOSIS GENERALLY
WO2019118873A2 (en) 2017-12-15 2019-06-20 Iovance Biotherapeutics, Inc. Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
EP3773691A4 (en) 2018-03-29 2022-06-15 Biodesix, Inc. Apparatus and method for identification of primary immune resistance in cancer patients
CN116685259A (zh) * 2020-10-19 2023-09-01 本-古里安大学B.G.内盖夫技术和应用公司 尿细菌对抗生素的敏感性的快速直接鉴定和确定

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1540010B8 (en) 2002-08-06 2010-07-14 The Johns Hopkins University Use of biomarkers for detecting ovarian cancer
CA2527321A1 (en) 2003-05-30 2004-12-23 Genomic Health, Inc. Gene expression markers for response to egfr inhibitor drugs
US20050267689A1 (en) 2003-07-07 2005-12-01 Maxim Tsypin Method to automatically identify peak and monoisotopic peaks in mass spectral data for biomolecular applications
US20050048547A1 (en) 2003-07-17 2005-03-03 Hongyu Zhao Classification of disease states using mass spectrometry data
AU2005231101A1 (en) 2004-03-30 2005-10-20 Eastern Virginia Medical School Lung cancer biomarkers
US20060029574A1 (en) 2004-08-06 2006-02-09 Board Of Regents, The University Of Texas System Biomarkers for diagnosis, prognosis, monitoring, and treatment decisions for drug resistance and sensitivity
WO2007001868A1 (en) * 2005-06-28 2007-01-04 Genentech, Inc. Egfr and kras mutations
US7908091B2 (en) * 2006-03-17 2011-03-15 Prometheus Laboratories Inc. Methods of predicting and monitoring tyrosine kinase inhibitor therapy
US7736905B2 (en) * 2006-03-31 2010-06-15 Biodesix, Inc. Method and system for determining whether a drug will be effective on a patient with a disease
US7858390B2 (en) 2006-03-31 2010-12-28 Biodesix, Inc. Selection of colorectal cancer patients for treatment with drugs targeting EGFR pathway

Similar Documents

Publication Publication Date Title
JP2012507033A5 (enExample)
JP2011513728A5 (enExample)
Onaitis et al. Prediction of long-term survival after lung cancer surgery for elderly patients in The Society of Thoracic Surgeons General Thoracic Surgery Database
Lima et al. Segregation of ovarian cancer stage exploiting spectral biomarkers derived from blood plasma or serum analysis: ATR‐FTIR spectroscopy coupled with variable selection methods
JP2015528110A5 (enExample)
WO2009049189A3 (en) Methods for detecting major adverse cardiovascular and cerebrovascular events
JP2013520681A5 (enExample)
de Vries et al. Prospective detection of early lung cancer in patients with COPD in regular care by electronic nose analysis of exhaled breath
CN102033043A (zh) 基于高光谱图像技术的粮粒含水率检测方法
WO2007109881A8 (en) Biomarkers useful for diagnosing prostate cancer, and methods thereof
EP2707710A1 (en) Diagnosis of cancer
JP2009538607A5 (enExample)
NZ719474A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
JP2009534667A5 (enExample)
WO2009074276A3 (en) Marker panel for colorectal cancer
EP2557413A3 (en) Blood analysis apparatus and blood analysis method
Mazzone et al. Progress in the development of volatile exhaled breath signatures of lung cancer
GB2494580A (en) Method for diagnosing lung cancer
WO2010037859A3 (en) Methods for predicting or monitoring whether a patient affected by a cancer is responsive to a treatment with a molecule of the taxoid family
WO2013016966A1 (zh) 检测肺癌蛋白的质谱模型及构建方法
EA201400131A1 (ru) Новый классификатор для молекулярной классификации миеломной болезни
Yang et al. Decreased macrophage inflammatory protein (MIP)‐1α and MIP‐1β increase the risk of developing nasopharyngeal carcinoma
CN103472124A (zh) 一种海洋生物及其制品的指纹鉴定方法
CN113736879B (zh) 用于小细胞肺癌患者预后的系统及其应用
ES2530357T3 (es) Método para detectar una infección con plasmodio